Aarti Pharmalabs Ltd announces Q1 FY 2026-27 results and role changes in management
Aarti Pharmalabs · Pharmaceuticals & Biotechnology
Key highlights
- Q1 standalone revenue from operations ₹534.59 crore; net profit ₹71.31 crore; EPS ₹7.87
- Change in designation effective October 1, 2026: Shri Rashesh C. Gogri appointed Managing Director; Smt. Hetal Gogri Gala changed to Executive Director, subject to shareholder approval
- Joint venture Ganesh Polychem Ltd contributed group share of net profit ₹7.41 crore for the quarter ended June 30, 2026
Why it's rated major development: the year-on-year change is 65% (50% or more)
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Approval Of Unaudited Financial Results (Standalone And Consolidated)For The Quarter Ended June 30, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Aarti Pharmalabs
- Financial resultsMajor developmentAarti Pharmalabs approves Sept 2026 results; CFO Piyush Lakhani resigns
- Board / shareholder meeting outcomeNotableAarti Pharmalabs Limited announces results of 7th AGM held on September 22, 2026
- Capex / expansionMajor developmentAarti Pharmalabs Limited reports Q1 FY 2026-27 results and approves director role changes
- Capex / expansionMajor developmentAarti Pharmalabs reports quarter ended June 30, 2026 results; approves Rs.149 Crores capex
- Capex / expansionNotableAarti Pharmalabs inaugurates new manufacturing block at Tarapur to expand capacity
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.